Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Other Non Operating Income (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Other Non Operating Income data on record, last reported at -$51000.0 in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 8.51% year-over-year to -$51000.0; the TTM value through Dec 2025 reached -$165000.0, down 0.61%, while the annual FY2025 figure was -$165000.0, 1.23% down from the prior year.
  • Other Non Operating Income reached -$51000.0 in Q4 2025 per CTNM's latest filing, down from $183000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $257000.0 in Q4 2023 and bottomed at -$167000.0 in Q2 2025.
  • Average Other Non Operating Income over 3 years is -$16833.3, with a median of -$41500.0 recorded in 2023.
  • The widest YoY moves for Other Non Operating Income: up 638.24% in 2025, down 2066.67% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at $257000.0 in 2023, then crashed by 118.29% to -$47000.0 in 2024, then dropped by 8.51% to -$51000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$51000.0 in Q4 2025, $183000.0 in Q3 2025, and -$167000.0 in Q2 2025.